Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ABL2 | P42684 | 1/20 | 0.37 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 9/20 | 0.35 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246941 | 1.00 | PRMT5 (0.41) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL18571707 | 0.92 | ABL1 (0.44) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL16769947 | 0.88 | PRMT5 (0.44) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL24753099 | 0.87 | PIP4K2A (0.44) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL1939828 | 0.84 | PIP4K2A (0.44) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL15636715 | 0.83 | PIP4K2A (0.45) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL1442965 | 0.83 | PIP4K2A (0.45) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL1442966 | 0.83 | PIP4K2A (0.45) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL17877686 | 0.83 | PIP4K2A (0.44) | PRMT5WDR77ABL1EGFRABL2 | |
| SCHEMBL30372589 | 0.83 | SLC22A12 (0.39) | PRMT5WDR77PIP4K2ASLC22A12ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | PRMT5 4294/4885WDR77 2751/4885ABL1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.